[S-40] Symposium 40「Nobel Prize research put into practical use one after another!　The cutting edge of ATTR amyloidosis treatment」

[S-40-3] CRISPR-based Gene Editing Therapy in Development for ATTR Amyloidosis

Liron Walsh (Intellia Therapeutics)

Liron Walsh is vice president and head of Development for Intellia’s in vivo programs. He has more than a decade of clinical development experience in the pharmaceutical and biotechnology industry, and has held multiple leadership roles in the advancement of rare disease programs through various stages of development. Prior to joining Intellia, Liron was the vice president of Clinical and Translational Nephrology at Goldfinch Biopharma advancing both small and large molecules into clinical trials for rare kidney disorders. Before Goldfinch, Liron served as a senior medical director at BioMarin, overseeing clinical development for gene therapy and enzyme replacement programs, including for Pompe disease and hemophilia A, and was a medical director in the Nephrology therapeutic area at Amgen. Liron received his MD from the University of Toronto and completed his Nephrology fellowship at Mount Sinai in NY.